Introduction
All drugs have the potential to cause side effects, also known as 'adverse drug reactions', but not all of these are allergic in nature. Other reactions are caused by drug intolerance, idiosyncratic reactions and pseudo-allergic reactions. The British Society for Allergy and Clinical Immunology (BSACI) defines drug allergy as an adverse drug reaction with an established immunological mechanism. The mechanism at presentation may not be apparent from the clinical history and it cannot always be established whether a drug reaction is allergic or non-allergic without investigation. Therefore, this guideline has defined drug allergy as any reaction caused by a drug with clinical features compatible with an immunological mechanism.
Hospital Episode Statistics from 1996 to 2000 reported that drug allergies and adverse drug reactions accounted for approximately 62,000 hospital admissions in England each year. There is also evidence that these reactions are increasing: between 1998 and 2005, serious adverse drug reactions rose 2.6-fold. Up to 15% of inpatients have their hospital stay prolonged as a result of an adverse drug reaction.
Almost 1 million people admitted to NHS hospitals each year have a diagnostic 'label' of drug allergy, with the most common being penicillin allergy. About 10% of the general population claim to have a penicillin allergy; this has often been because of a skin rash that occurred during a course of penicillin in childhood. Fewer than 10% of people who think they are allergic to penicillin are truly allergic. Therefore, penicillin allergy can potentially be excluded in 9% of the population.
Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac, naproxen and aspirin, is common. In particular, it affects 5-10% of people who have asthma. In these people, fatal reactions can occur with small doses of NSAIDs. One-third of people with chronic urticaria have severe reactions to NSAIDs, involving angioedema and anaphylaxis. 10,000-20,000 anaesthetics. These patients may be denied general anaesthesia in the future unless a safe combination of drugs can be identified.
Major issues identified by this guideline include poor clinical documentation of drug allergy and a lack of patient information. Computerised primary care record systems are often unable to distinguish between intolerance and drug allergy and this can lead to a false label of drug allergy, particularly if the person's reaction took place many years previously and details about their reaction have been lost. Furthermore, there is no routine system in place for people to keep a record of their own drug allergies. This can lead to confusion over which drugs can be taken safely and can result in people inadvertently taking a drug they are allergic to, particularly when buying over-the-counter drugs from a pharmacy.
Analysis of patient safety incidents reported to the National Reporting and
Learning System between 2005 and 2013 identified 18,079 incidents involving drug allergy. These included 6 deaths, 19 'severe harms', 4,980 'other harms' and 13,071 'near-misses'. The majority of these incidents involved a drug that was prescribed, dispensed or administered to a patient with a previously known allergy to that drug or drug class.
Diagnosing drug allergy can be challenging and there is considerable variation both in how drug allergy is managed and in geographical access to treatment.
This can lead to under diagnosis, misdiagnosis and self-diagnosis. This variation may be caused by insufficient awareness of available services or by a lack of local provision of drug allergy centres. Some people are never offered referral to specialist services and instead stay in primary care while others have their drug allergy managed in other disciplines. Therefore, only a small proportion of people are treated in specialist allergy centres.
In view of the variation in provision of care for people with drug allergy, the scope of this guideline identified a need for guidance to improve clinical management for people affected by drug allergy. This guideline has been developed for use by healthcare professionals at all levels of healthcare and offers best practice advice on the diagnosis, documentation and communication of drug allergy in adults, children and young people.
Drug recommendations
The guideline will assume that prescribers will use a drug's summary of product characteristics to inform decisions made with individual patients.
Patient-centred care
This guideline offers best practice advice on the care of adults, children and young people with suspected or confirmed drug allergy. should be planned and managed according to the best practice guidance described in the Department of Health's Transition: getting it right for young people.
Adult and paediatric healthcare teams should work jointly to provide assessment and services to young people with drug allergies. Diagnosis and management should be reviewed throughout the transition process, and there should be clarity about who is the lead clinician to ensure continuity of care.
Strength of recommendations
Some recommendations can be made with more certainty than others. The
Guideline Development Group makes a recommendation based on the tradeoff between the benefits and harms of an intervention, taking into account the quality of the underpinning evidence. For some interventions, the Guideline Development Group is confident that, given the information it has looked at, most patients would choose the intervention. The wording used in the recommendations in this guideline denotes the certainty with which the recommendation is made (the strength of the recommendation).
For all recommendations, NICE expects that there is discussion with the patient about the risks and benefits of the interventions, and their values and preferences. This discussion aims to help them to reach a fully informed decision (see also 'Patient-centred care').
Interventions that must (or must not) be used
We usually use 'must' or 'must not' only if there is a legal duty to apply the recommendation. Occasionally we use 'must' (or 'must not') if the consequences of not following the recommendation could be extremely serious or potentially life threatening.
Interventions that should (or should not) be used -a 'strong' recommendation
We use 'offer' (and similar words such as 'refer' or 'advise') when we are confident that, for the vast majority of patients, an intervention will do more good than harm, and be cost effective. We use similar forms of words (for example, 'Do not offer…') when we are confident that an intervention will not be of benefit for most patients.
Interventions that could be used
We use 'consider' when we are confident that an intervention will do more good than harm for most patients, and be cost effective, but other options may be similarly cost effective. The choice of intervention, and whether or not to have the intervention at all, is more likely to depend on the patient's values and preferences than for a strong recommendation, and so the healthcare professional should spend more time considering and discussing the options with the patient.
Key priorities for implementation
The following recommendations have been identified as priorities for implementation. The full list of recommendations is in Section 1.
Assessment
 When assessing a person presenting with possible drug allergy, take a history and undertake a clinical examination. Use the following tables as a guide when deciding whether to suspect drug allergy.  Allergy specialists should give the following written information to people who have undergone specialist drug allergy investigation:
 the diagnosis -whether they had an allergic or non-allergic reaction  the drug name and a description of their reaction  the investigations used to confirm or exclude the diagnosis  drugs to avoid in future  any safe alternative drugs that may be used. 
Recommendations
The following guidance is based on the best available evidence. The full guideline [hyperlink to be added for final publication] gives details of the methods and the evidence used to develop the guidance.
All recommendations apply to adults, children and young people. Be aware that the reaction is more likely to be caused by drug allergy if it occurred during or after use of the drug and:
Assessment
 the drug is known to cause that type of reaction or  the person has had a similar reaction to that drug or class of drug in a previous exposure.
1.1.3
Be aware that the reaction is less likely to be caused by drug allergy if:
 there is a possible non-drug cause for the person's symptoms, for example, they have had similar symptoms when not taking the drug, or  the person has gastrointestinal symptoms only.
Measuring serum tryptase after suspected anaphylaxis 1.1.4 After a suspected drug-related anaphylactic reaction, take blood samples for mast cell tryptase in line with recommendations in Anaphylaxis (NICE clinical guideline 134).
1.1.5
Record in the person's notes and on the pathology request form, the exact timing of both blood samples taken for mast cell tryptase after onset of suspected anaphylaxis.
1.1.6 Ensure that tryptase sampling tubes are included in emergency anaphylaxis kits.
Measuring serum specific immunoglobulin E (IgE)
1.1.7 Do not use blood testing for specific IgE for diagnosing drug allergy in a non-specialist setting.
Documenting and sharing information with other healthcare professionals
Recording drug allergy status 1.2.1 Healthcare professionals should document people's drug allergy status in their healthcare records using 1 of the following:
 'unable to ascertain' (document it as soon as the information is available).
1.2.2
When documenting suspected or confirmed drug allergy status in routine care, record all of the following at a minimum: Maintaining and sharing drug allergy information
1.2.4
Ensure that drug allergy status is documented separately from adverse drug reactions and that it is clearly visible to all healthcare professionals who are prescribing, administering and dispensing drugs.
1.2.5
Check drug allergy status and update, if needed, at every contact with the patient.
1.2.6
Check and update a person's documented drug allergy status and confirm it with the person (or their parents or carers if appropriate) before prescribing, dispensing or administering any drug.
1.2.7
Carry out medicines reconciliation for people admitted to hospital in line with recommendations in Technical patient safety solutions for medicines reconciliation on admission of adults to hospital (NICE patient safety solutions 1).
Ensure that information about drug allergy status is included in all:
 GP referral letters  prescriptions issued in any healthcare setting.
After specialist drug allergy investigations
For recommendations on referral to specialist services see section 1.4.
1.2.9
After specialist drug allergy investigations, allergy specialists should document:
 the diagnosis -whether the person had an allergic or nonallergic reaction  the investigations used to confirm or exclude the diagnosis  drug or drug classes to avoid in future. aware of the drug or drug classes that they need to avoid, and advise them to check with a pharmacist before taking any over-thecounter drugs.
Providing information and support to patients

1.3.3
Advise people (and their parents or carers if appropriate) to carry information they are given about their drug allergy at all times and to share this whenever they visit a healthcare professional or are prescribed, dispensed or are about to be administered a new drug.
1.3.4
Allergy specialists should give the following written information to people who have undergone specialist drug allergy investigation:
 the diagnosis -whether they had an allergic or non-allergic reaction  the drug name and a description of their reaction  the investigations used to confirm or exclude the diagnosis  drugs to avoid in future  any safe alternative drugs that may be used.
1.3.5
Inform people in whom allergy to a drug or drug class has been excluded by specialist investigation that they can now take this drug or drug class safely. 
1.4.9
Consider referring to a specialist drug allergy service people who are not able to take beta-lactam antibiotics and at least 1 other class of antibiotic because of suspected allergy to these antibiotics.
Local anaesthetics
1.4.10
Refer to a specialist drug allergy service people who need procedures involving local anaesthetics but are unable to have them because of previous suspected allergic reactions to local anaesthetics.
General anaesthesia
1.4.11
Refer to a specialist drug allergy service people who have had a suspected allergic reaction or anaphylaxis during or immediately after general anaesthesia.
Research recommendations
The Guideline Development Group has made the following recommendations for research, based on its review of evidence, to improve NICE guidance and patient care in the future. The Guideline Development Group's full set of research recommendations is detailed in the full guideline.
Designing systems for documenting drug allergy
Which documentation strategies would be most clinically and cost effective to minimise the number of people who are re-exposed to drugs to which they have a suspected or confirmed allergy, looking in particular at:
 electronic health records that include features specifically designed to record and alert clinicians to drug allergy information, compared with systems without such features, and  different formats for patient-held, structured drug allergy documentation?
Why is this important?
Evidence from patient safety incident reports to the National Reporting and Learning System and from published research shows that a large number of NHS patients with known drug allergies are being re-exposed to these drugs Most of the studies included in the systematic review were from the USA and their focus was largely on adverse drug events or medication prescribing errors, and not specifically on drug allergy. In addition, few studies assessed the effectiveness of patient-held documentation strategies. The quality of the evidence from studies was generally very low. Research is therefore needed to determine which strategy or combination of strategies is most effective in reducing harm by minimising accidental re-exposure to a known drug allergen.
Communicating information about drug allergy
In people with suspected or confirmed drug allergies, are patient-focused information strategies more effective than standard NHS practice in increasing people's likelihood of disclosing their drug allergy (or their suspected drug allergy) and therefore reducing the risk of being re-exposed to the affected drug?
Why is this important?
Administering drugs to which patients have a reported allergy can be fatal, but inadvertent prescription or administration of such drugs is common. Research is therefore needed to determine which information strategy would be most effective (and preferred by patients) to:
 increase patients' knowledge about their allergy and ability to remember this information  increase patient empowerment and confidence to discuss their drug allergy with healthcare professionals  minimise harm from inadvertent re-exposure to a suspected drug allergen.
2.3
Using selective cyclooxygenase 2 inhibitors in people with previous severe allergic reactions to nonselective non-steroidal anti-inflammatory drugs
Should all patients who have experienced a severe allergic reaction to a nonselective non-steroidal anti-inflammatory drug (NSAID) be assessed by specialist drug allergy services or should they be advised to take a selective cyclooxygenase 2 (COX-2) inhibitor without further investigations?
Why is this important?
There are 5.4 million people with asthma in the UK, 1-5% of whom are unable to take non-selective NSAIDs without developing a severe and sometimes lifethreatening asthma attack. In addition, 0.1-1% of the general population report allergic reactions to NSAIDs with symptoms ranging from urticaria and angioedema to anaphylaxis. NSAIDs are extremely widely used, are available over the counter and are present within many compound preparations, for example cold and flu remedies. People who are allergic to NSAIDs are therefore at risk of inadvertent exposure and this presents a significant public health issue.
Commonly encountered NSAIDs such as aspirin, ibuprofen, diclofenac and naproxen are non-selective COX-2 inhibitors which block the enzymatic effects of both cyclooxygenase 1 (COX-1) and COX-2. More recently introduced NSAIDs include a group which are selective inhibitors of the COX-2 isoform alone. Studies have shown that the allergic response to NSAIDs is mediated through inhibition of COX-1 and therefore the majority of people with a history of allergic reactions to non-selective NSAIDs are able to tolerate selective COX-2 inhibitors. However, the same studies have also reported that a small proportion of these people also react adversely to selective COX-2 inhibitors. This group has not been properly characterised and therefore it is not possible to predict who should be offered a selective COX-2 inhibitor without undertaking specialist drug allergy investigations. This clinical guideline recommends that people with a history of mild reactions should be offered a selective COX-2 inhibitor but that all those with severe or asthmatic reactions be referred to specialist drug allergy services for investigation before they can be offered treatment.
Well-designed, appropriately powered, controlled studies characterising people with a history of severe and asthmatic reactions to non-selective NSAIDs may enable them to have treatment with an anti-inflammatory without specialist drug allergy investigation.
Oral antibiotic challenge for diagnosing antibiotic allergy in children
In children who have a suspected allergy to an antibiotic, is it clinically and cost effective to proceed directly (without prior skin or intra-dermal tests) to a diagnostic oral antibiotic challenge rather than refer to specialist drug allergy services?
Why is this important?
Antibiotics are an important class of drug and one of the most common groups of drugs prescribed to children. Many childhood illnesses are associated with skin rashes, and it can be clinically difficult in the acute setting to be certain if an atypical rash is caused by the underlying illness, the antibiotic, or both.
Adverse drug reactions to antibiotics are common and frequently result in a child being diagnosed with 'drug allergy', a diagnosis which generally remains for life.
Current clinical experience suggests that most patients in a community setting who are believed to be allergic to an oral antibiotic (approximately 3% for children, 10-20% for adults) will be challenge 'negative' -that is, they are able to tolerate the oral antibiotic on the day of the challenge and on subsequent days. While patients who are correctly diagnosed with an allergy are kept safe through avoidance, there are health and cost implications for patients who are incorrectly diagnosed with an antibiotic allergy.
The evidence review for this clinical guideline found no evidence to support the reliability of allergy testing (skin, intradermal or IgE determination) for the diagnosis of antibiotic allergy in children. In addition, these tests are painful and restricted to only a few specialist centres in the UK. The result is that only a small fraction of children in the UK with a diagnosis of antibiotic allergy ever undergo investigations to confirm or exclude this diagnostic 'label'. It would therefore be beneficial to prospectively investigate the use of the oral supervised challenge in a safe clinical setting without prior allergy testing. This novel diagnostic approach could be compared with an intervention of 'antibiotic avoidance'.
